Skip to content

Simplified Medical Abortion in Rural India

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01827995
Enrollment
731
Registered
2013-04-10
Start date
2013-04-30
Completion date
2014-06-30
Last updated
2014-08-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy

Keywords

Low sensitivity urinary hCG, follow up, medical abortion, rural India, RCT

Brief summary

It is estimated that around 50 000 women die every year due to consequences of unsafe abortion (Singh et al, 2009). A majority of these deaths occur in low-income countries where access to safe abortion care is limited. Unplanned pregnancy and unsafe abortion thus place a huge burden on scarce medical resources. Any improvement in Comprehensive Abortion Care (CAC) would mean important improvements for the concerned women and their families (Singh, 2006) as well as for the societies at large. Recommended improvements concern increased access to the safest and most cost-effective methods such as medical abortion provided at primary level facilities (Singh et al, 2009). A Cochrane Review concludes that most randomised controlled trials within the field of medical abortion are conducted in high-income settings with good access to emergency health care services (Kulier et al, 2004). A simplified regime for medical abortion, which could be used at primary level facilities, would contribute to the reduction of maternal mortality and morbidity related to unsafe abortions globally. However, there is a knowledge gap in order to determine if a simplified follow up of medical abortion is equally effective as the standard procedure in a low-income setting. The results will provide evidence-based information to be used in revising training and service delivery guidelines' in order to reduce maternal mortality and morbidity in both low and high-income setting.

Interventions

Intervention group: Simplified followup Mifepristone at outpatient clinic, followed by the administration of misoprostol 24-48 hours later (in the clinic or at home). The women will not return to the clinic for routine follow up visit, but are given instructions on how to use a checklist and a low sensitivity pregnancy test around day 10-14. They are asked only to return if they have any health problems or screen positively. The low sensitivity urinary-hCG (with HCG of 1000 IU/ml) test will be used. Women will be provided the pregnancy test free of cost along with a pictorial checklist. A research assistant or a nurse will explain in detail how to use the pregnancy test as well as the checklist, and provide phone numbers in case of any questions or doubts. Follow-up interviews will be conducted through home visits or phone (if woman has one) during the next 1-2 days to screen for on-going pregnancies and assess acceptability the self-assessment.

OTHERRoutine assessment

Follow up in the clinic

Sponsors

Karolinska Institutet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* women presenting with a positive urine test and uterine size equivalent to or up to 9 +0 weeks (63 days) of gestation * opting for medical abortion and * residing in an area where follow-up is feasible. * woman agrees for a follow up contact at 10-14 days.

Exclusion criteria

* women with contraindications to medical abortions, * haemoglobin level less than 85 (Hb \< 85) and * age less than 18 years.

Design outcomes

Primary

MeasureTime frameDescription
EfficacyAt 10-14 days follow upefficacy of self-assessment, measured as the rate of complete abortion, relative to routine follow up . The percentage of women requiring surgical intervention, extra visits and administration of additional misoprostol will be used to monitor incomplete abortion.

Secondary

MeasureTime frameDescription
SafetyUp to 10-14 days Follow Upunscheduled visits for various adverse events/complications, side effects of medical abortion including infections, bleeding, pain

Other

MeasureTime frameDescription
contraceptive uptakeat approx. 2 weeks after abortion (at FU)Number of women who have started a contraceptive method or is planning to start a method
time consumptionat 10-14 days Follow UpTime spent for clinical visits/contacts
Acceptabilityat 10-14 days follow upAcceptability (evaluated by a questionnaire)of home self assessment of complete pregnancy using a low sensitivity u-hCG test

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 19, 2026